Emisphere Technologies, Inc. (OTCBB:EMIS) reported positive Phase 2 OG217SC Data from its Eligen® licensee Novo Nordisk. The data is related to the oral formulation of semaglutide that suppresses glucagon secretion and stimulates insulin. The medication is given in a tablet formulation with SNAC. It is an absorption enhancing excipient and is covered in the Eligen® Carrier Concept.
The positive data
Emisphere Technologies, Inc. (OTCBB:EMIS) through Novo Nordisk reported that it had completed the Phase 2 trial for its drug candidate OG217SC. The Phase 2 trial included investigating dose range, efficacy, safety and escalation of once-daily oral semaglutide. The experimental drug was compared with oral placebo in around 600 people suffering from Type 2 diabetes. The study was carried out for 26 weeks. Based on the results, the company said it will commence consultations with regulatory agencies, following which phase 3 will be planned.
The management view
Alan L. Rubino, the CEO and President of Emisphere Technologies, Inc. (OTCBB:EMIS), said that there are many key issues in developing an oral formulation of GLP-1. OG217SC addresses some of the issues by using Eligen® Technology to smoothen absorption from the gastrointestinal tract. It aims to eliminate major hurdles in effective oral delivery including poor absorption and drug degradation.
Under GLP-1 License Deal, Novo Nordisk will look after development and commercialization of oral formulations of GLP-1 receptor agonists together with Emisphere Technologies, Inc. (OTCBB:EMIS) carriers. Emisphere will receive additional payments from additional contingent product sales. It will also be entitled to get royalties in case Novo commercializes products developed under such deal. As per deal, Novo will be responsible for
Semaglutide and OG217SC
Semaglutide can be defined as a long-acting ‘human GLP-1’ analogue. It is in development for subcutaneous use extending once in a week. It was administered in oral form, once in a day to patients suffering from type 2 diabetes. The oral formulation named as OG217SC is provided in tablet form with SNAC. OG217SC and Semaglutide are Novo Nordisk product candidates.